Julian Harrison

“I'll limit myself to one question and what I'd love to get your perspective on more is any read-through to ResPeg's remittive potential in atopic dermatitis.”

“I have a few, and I think I'll ask them all at once. First, thinking about your $500 million in U.S. sales by 2030 guidance, I understand that does assume repackaged bevacizumab is still available.”

“I think our goal is to get into the market, demonstrate what the quality and the reimbursement and the experiences with us and then and grow from there and then obviously expand that as we get the permanent j code super thanks i'll get back in the queue thank you thank you the next question comes from douglas sal with…”

“First, I'm wondering if you have any updated views on ResPeg's competitive positioning in alopecia areata in light of a recent data set last month from another non-JAC treatment option in development in the broader space.”

“I have three, and I'll just ask them all at once. First, considering your recently expanded Salesforce, I'm wondering how you're thinking about the balance between deepening relationships with existing prescribers of Eutropia versus expanding your prescriber base going forward.”